For close to the 37 years, HIV has been one of Uganda’s highest burden infectious diseases causing both mortality and morbidity in varying proportions. By 2016, Uganda had an HIV prevalence of 6.2% among adults aged between 15-49; an estimated 1.3 million adults and 96,000 children living with HIV (UNAIDS report 2016, UPHIA 2016-2017). The government of Uganda continues to work with several donors, collaborating institutions and civil society organizations to provide lifelong treatment. Out of the 1.3 million PLHIV, 1.1 million are accessing ART.

12th JAR Report -2019

This report presents the country progress of the fourth year of Uganda’s NSP (2015/16 -2019/20) implementation that builds on previous achievements since 2017/18. The report is divided into three (3) main sections which include; the introduction part that summarizes the review approach and report compilation process, the overview of HIV epidemic in Uganda and, the progress made during the FY 2018/19.


World AIDS Day is an annual event that is globally commemorated on 1st December. The global theme for this year’s World AIDS Day was ‘Communities make the difference.’ This was in recognition of the important leadership and advocacy done by communities to ensure that the response remains relevant and grounded. Uganda proceeded with the customized theme ‘Empowering Young People to champion the end of new HIV infections’.


Uganda has been affected by the HIV and AIDS epidemic since 1980’s. The HIV prevalence is still high at 6.2% (UPHIA 2017). A lot of efforts have been put in the response to reduce the HIV/AIDS prevalence from the previous higher levels, but more resources are still needed to achieve the 2030 targets of having HIV and AIDS as no longer a public health threat. This needs concerted funding, planning and coordination of efforts from different stakeholders.


The Uganda Population-based HIV Impact Assessment (UPHIA) 2016-2017 was a nationally representative, cross-sectional, population-based survey of households across Uganda. UPHIA focused on measuring key biological endpoints to provide direct estimates of HIV infection, risk, and burden and of the effectiveness and population-level impact of the HIV-related prevention, care, and treatment interventions implemented in the country.